Skip to main content
SpringerLink
Log in

A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Thirty-two patients with advanced breast cancer refractory to combination chemotherapy with cyclophosphamide (CPA), doxorubicin (ADR) and 5-fluorouracil (5-FU) (CAF) were treated with the combination of mitomycin C, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy. Observed responses included 6 patients (18.7%) with complete response (CR) and 7 (21.9%) with partial response (PR). Two (50%) out of 4 patients who had bone pain due to bone metastasis noted pain relief. CR or PR were obtained in 4 out of 12 patients who had not responded to the previous CAF therapy. While grade III myelosuppression was observed in 3 patients, other adverse effects were minimal. It is suggested that this combination therapy may be recommended for advanced breast cancer patients as a second therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

MMC:

Mitomycin C

CPA:

Cyclophosphamide

ADR:

Doxorubicin

5-FU:

5-Fluorouracil

MPA:

Medroxyprogesterone acetate

VP-16:

Etoposide

5’DFUR:

Doxifluridine

References

  1. Tranum B, Hoogstraten B, Kennedy A,et al: Adriamycin in combination for the treatment of breast cancer.Cancer 41:2078–2083, 1978.

    Article  PubMed  CAS  Google Scholar 

  2. Tormey DC, Weinberg VE, Leone LA,et al: A comparison of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer.Am J Clin Oncol 7:231–239, 1984.

    Article  PubMed  CAS  Google Scholar 

  3. Yoshinaka K, Yagi M, Ohtagaki S,et al: 5’-deoxy- fluorouridine (5’DFUR), mitomycin C (MMC), etoposide and medroxyprogesterone acetate (MPA) in a previously treated patient with advanced breast cancer.Jpn J Cancer Chemother 18:115–118, 1991 (in Japanese with English summary).

    CAS  Google Scholar 

  4. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 11th ed, Kanehara, Tokyo, pp1–61, 1992.

    Google Scholar 

  5. van Oosterom AT, Powles TJ, Hamersma E,et al: A phase II study of mitomycin C in refractory advanced breast cancer; A multi-centre pilot study. In: Mouridsen HT, Palshof T eds, Breast Cancer; Experimental and Clinical Aspects, Pergamon Press, Elmsfold, pp275–276, 1980.

    Google Scholar 

  6. Creech RH, Catalano RB, Shah MK,et al: An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer.Cancer 51:1034–1040, 1983.

    Article  PubMed  CAS  Google Scholar 

  7. De Lena M, Jirillo A, Branbilla C,et al: Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.Tumori 66:481- 487, 1980.

    PubMed  Google Scholar 

  8. Hortobagi GN: Mitomycin; Its evolving role in the treatment of breast cancer.Oncology 50:1–8, 1993.

    Google Scholar 

  9. Walters RS, Frye D, Buzdar AU,et al: A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma.Cancer 69:476–481, 1992.

    Article  PubMed  CAS  Google Scholar 

  10. Konits P, Aisner J, VanEcho D,et al: Mitomycin C and vinblastine chemotherapy for advanced breast cancer.Cancer 48:1295–1298, 1981.

    Article  PubMed  CAS  Google Scholar 

  11. Perrone F, De-Placido S, Carlomagno C,et al: Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.Tumori 79:254- 257, 1993.

    PubMed  CAS  Google Scholar 

  12. Cavalli F: VP-16-213 (Etoposide), a critical review of its activity.Cancer Chemother Pharmacol 7:81–85, 1982.

    Article  PubMed  CAS  Google Scholar 

  13. Rubin J, Decker DA, Ahmann DL,et al: An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.Oncology 37:149- 151, 1980.

    Article  PubMed  CAS  Google Scholar 

  14. Vaughn CB, Enochs C, Maniscalco-Greb E,et al: VP- 16 and adriamycin in patients with advanced breast cancer.Am J Clin Oncol 5:505–507, 1982.

    PubMed  CAS  Google Scholar 

  15. Krook JE, Loprinzi CL, Schaid DJ,et al: Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer; A collaborative north central cancer treatment group/Mayo clinic phase II study.Cancer 65:418–421, 1990.

    Article  PubMed  CAS  Google Scholar 

  16. Issel BF, Crooke ST: Etoposide (VP 16-231).Cancer Treat Rev 6:107–124, 1979.

    Article  Google Scholar 

  17. Schell FC, Yap HY, Hortobagyi GN,et al: Phase II study of VP16-213 (Etoposide) in refractory metastatic breast cancer.Proc Am Soc Clin Oncol 22:357, 1981.

    Google Scholar 

  18. Manga GP, Alonso PLM, Carbuccia HA: Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.Cancer Chemother Pharmacol 7:227–229, 1982.

    Google Scholar 

  19. Koyama H, Nishizawa Y, Noguchi S,et al: A combination therapy with 5’DFUR and MPA as a second line treatment for advanced/recurrent breast cancer.J Jpn Soc Cancer Ther 25:655–661, 1990 (in Japanese with English summary).

    CAS  Google Scholar 

  20. Pannuti F, Martoni A, Lenaz GR,et al: A possible new approach to the treatment of metastatic breast cancer; Massive doses of medroxyprogesterone acetate.Cancr Treat Rep 62:499–504, 1978.

    CAS  Google Scholar 

  21. Taguchi T, Sakai K, Terasawa T,et al: Phase II study of 5’DFUR (5’-deoxy-5-fluorouracil) by cooperative study group.Jpn J Cancer Chemother 12:2179- 2184, 1985 (in Japanese with English summary).

    CAS  Google Scholar 

  22. Rowinsky EK, Harwood KV, Ettinger DS: Sudden dyspnea occuring 24 hours after mitomycin plus etoposide combination therapy.Cancer Treat Rep 71: 103–104, 1987.

    PubMed  CAS  Google Scholar 

  23. Wada T, Nishiyama K, Nakatani Y,et al: CAF versus CAF plus medroxyprogesterone acetate for treatment of liver metastases of breast cancer.Breast Cancer 2:65–70, 1995.

    Article  PubMed  Google Scholar 

  24. Nishimura R, Nagao K, Matsuda M,et al: Benefits of medroxyprogesterone acetate (MPA) in advanced or recurrent breast cancer with higher serum concentration.Breast Cancer 2:133–141, 1995.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, 734, Minami-ku, Hiroshima, Japan

    Katsumasa Kuroi, Akihiko Osaki, Hiroyuki Kawami, Shigeru Murakami & Tetsuya Toge

Authors
  1. Katsumasa Kuroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiko Osaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Kawami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigeru Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Toge
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kuroi, K., Osaki, A., Kawami, H. et al. A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil. Breast Cancer 4, 115–119 (1997). https://doi.org/10.1007/BF02967064

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967064

Key words

Search

Navigation